Urethral toxicity after LDR brachytherapy: Experience in Japan - Abstract

Urinary toxicity is common after low-dose-rate (LDR) brachytherapy, and the resolution of urinary toxicity is a concern.

In particular, urinary frequency is the most common adverse event among the urinary toxicities. We have previously reported that approximately 70% of patients experience urinary frequency during the first 6 months after seed implantation. Most urinary adverse events were classified as Grade 1, and Grade 2 or higher adverse events were rare. The incidence of urinary retention was approximately 2-4%. A high International Prostate Symptom Score before seed implantation was an independent predictor of acute urinary toxicity of Grade 2 or higher. Several previous reports from the United States also supported this trend. In Japan, LDR brachytherapy was legally approved in 2003. A nationwide prospective cohort study entitled Japanese Prostate Cancer Outcome Study of Permanent Iodine-125 Seed Implantation was initiated in July 2005. It is an important issue to limit urinary toxicities in patients who undergo LDR brachytherapy.

Written by:
Tanaka N, Asakawa I, Hasegawa M, Fujimoto K.   Are you the author?
Department of Urology, Nara Medical University, Kashihara, Japan; Department of Radiation Oncology, Nara Medical University, Kashihara, Japan.  

Reference: Brachytherapy. 2014 Nov 6. pii: S1538-4721(14)00661-8.
doi: 10.1016/j.brachy.2014.09.009.


PubMed Abstract
PMID: 25455383

UroToday.com Prostate Cancer Section